Cargando…

RUNX inhibitor suppresses graft‐versus‐host disease through targeting RUNX‐NFATC2 axis

Patients with refractory graft‐versus‐host disease (GVHD) have a dismal prognosis. Therefore, novel therapeutic targets are still needed to be identified. Runt‐related transcriptional factor (RUNX) family transcription factors are essential transcription factors that mediate the essential roles in e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubota, Hirohito, Masuda, Tatsuya, Noura, Mina, Furuichi, Kana, Matsuo, Hidemasa, Hirata, Masahiro, Kataoka, Tatsuki R., Hiramatsu, Hidefumi, Yasumi, Takahiro, Nakahata, Tatsutoshi, Imai, Yoichi, Takita, Junko, Adachi, Souichi, Sugiyama, Hiroshi, Kamikubo, Yasuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Haematologic Malignancy ‐ Cellular Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175814/ https://www.ncbi.nlm.nih.gov/pubmed/35844683 http://dx.doi.org/10.1002/jha2.230

Ejemplares similares

RUNX1–Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors
por: Mikami, Masamitsu, et al.
Publicado: (2022)

RUNX1 transactivates BCR‐ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia
por: Masuda, Tatsuya, et al.
Publicado: (2021)

Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells
por: Morita, Ken, et al.
Publicado: (2017)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice
por: Hattori, Etsuko Yamamoto, et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Author Correction: A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice
por: Hattori, Etsuko Yamamoto, et al.
Publicado: (2022)

RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells
por: Mitsuda, Yoshihide, et al.
Publicado: (2018)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Genetic compensation of RUNX family transcription factors in leukemia
por: Kamikubo, Yasuhiko
Publicado: (2018)

Differences in incidence and trends of haematological malignancies in Japan and the United States
por: Chihara, Dai, et al.
Publicado: (2014)

CROX (Cluster Regulation of RUNX) as a Potential Novel Therapeutic Approach
por: Kamikubo, Yasuhiko
Publicado: (2020)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
por: Leupin, Nicolas, et al.
Publicado: (2006)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
por: Kohlmann, Alexander, et al.
Publicado: (2008)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
por: Smith, Alexandra, et al.
Publicado: (2010)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

CXCR2 modulates bone marrow vascular repair and haematopoietic recovery post‐transplant
por: Hale, Sarah J. M., et al.
Publicado: (2015)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015)

A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
por: Niavarani, Ahmadreza, et al.
Publicado: (2016)

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy
por: Sarid, Nadav, et al.
Publicado: (2015)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gb87dsban7tv44ld0fg0kveb27